Summary
This 8-K filing from Pfizer Inc. (PFE) on November 5, 2020, primarily serves to announce details regarding the upcoming 'when-issued' trading of Viatris Inc. common stock and 'ex-distribution' trading of Pfizer common stock. This relates to the previously announced spin-off of Pfizer's Upjohn Business and its subsequent combination with Mylan N.V. to form Viatris. Investors should pay attention to these trading mechanics as they signal the imminent completion of this significant strategic transaction.
Key Highlights
- 1Announcement of 'when-issued' trading for Viatris Inc. common stock.
- 2Announcement of 'ex-distribution' trading for Pfizer Inc. common stock.
- 3Details provided in connection with the spin-off of Pfizer's Upjohn Business.
- 4Information relates to the proposed combination of the Upjohn Business with Mylan N.V. to form Viatris.
- 5The press release attached as Exhibit 99.1 contains the specific details of these trading arrangements.
- 6This filing indicates the transaction is progressing towards completion.
Frequently Asked Questions
'When-issued' trading refers to trading that occurs before a security is formally issued. In this context, it allows investors to trade Viatris shares before they are officially distributed as part of the spin-off transaction.
'Ex-distribution' trading means that the stock is trading without the right to receive the upcoming distribution. For Pfizer shareholders, trading on an 'ex-distribution' basis means they will not receive shares of Viatris if they sell their Pfizer shares after a certain date.
The Upjohn Business is Pfizer's global, primarily off-patent branded and generic established medicines business, which is being spun off and combined with Mylan N.V. to create a new company named Viatris Inc.
This 8-K filing from November 5, 2020, does not provide a specific completion date but details the trading arrangements that precede it, suggesting the transaction is nearing its close.